
Arndt Vogel/X
Apr 28, 2025, 08:02
Arndt Vogel Highlights Advances and Challenges in HER2-Targeted Therapies for Colorectal Cancer
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology at Hannover Medical School, shared on X:
“Advances and challenges in targeted therapies for HER2-amplified CRC, European J Cancer.
- Excellent review HER2
- overexpressed in ~6% of RAS WT
- Trastuzumab/Tucatinib and T-Deruxtecan FDA approved , but still many open questions.”
Advances and challenges in targeted therapies for HER2-amplified colorectal cancer
Authors: Margot Pizzamiglio et al.
More posts featuring Arndt Vogel on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 28, 2025, 07:42
Apr 28, 2025, 06:14
Apr 28, 2025, 04:27
Apr 28, 2025, 03:56
Apr 28, 2025, 03:45